期刊
ATHEROSCLEROSIS
卷 207, 期 2, 页码 552-558出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2009.05.015
关键词
Cystatin C; Acute coronary syndromes; Prognosis
资金
- Kocaeli University, Turkey [Unit 2007/055]
Objective: Emerging evidence indicates the prognostic importance of Cystatin C (Cys-C) in patients with coronary artery disease. However, whether Cys-C concentrations are associated with adverse clinical events among patients with acute coronary syndromes (ACS) have not been studied extensively. We compared the long-term prognostic efficacy of Cys-C with other markers of renal dysfunction, inflammation and systolic dysfunction in patients with ACS. Methods and results: Serum levels of Cys-C, high sensitive C-reactive protein (hs-CRP), brain natriuretic peptide (BNP) and creatinine were measured in 160 patients with ACS (112 males, 48 females, mean age 60 +/- 10 years) on admission. Primary end point of the study was major adverse cardiac events (MACE) defined as the combination of cardiac death, non-fatal myocardial infarction and recurrent rest angina that required hospitalization within 12 months of follow-up. During the follow-up period, 42 (26%) patients met the MACE criteria. The occurrence of MACE was significantly higher among patients with higher Cys-C levels. In multivariate analysis, Cys-C was the most important parameter associated with the occurrence of MACE (OR = 9.62, 95% CI = 2.3-40.5, p < 0.001). ROC curve analysis showed that the predictive cut-off value of Cys-C for MACE was 1051 ng/ml. In the Cox regression analysis adjusted for multiple risk factors, Cys-C was found as the most powerful predictor for MACE (RR = 9.43, 95% CI = 4.0-21.8, p < 0.001). Conclusion: The results of the present study indicate that admission levels of Cys-C may be a good prognostic indicator of recurrent cardiovascular events in patients with ACS. Further studies are needed to confirm these results. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据